Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mucopolysaccharidosis type VII: A powerful experimental system and therapeutic challenge.

Pediatric endocrinology reviews : PER - 1 Sept 2014

Sands Mark S

Abstract excerpt

Mucopolysaccharidosis type VII (MPSVII) is an inborn error of metabolism caused by a deficiency in the lysosomal enzyme B-glucuronidase (GUSB). As such, MPSVII is one of a larger class of inherited diseases referred to as lysosomal storage diseases (LSD). (1) The absence of GUSB activity leads to the progressive accumulation of undegraded glycosaminoglycans (GAGs) in many tissues of the body....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Transplantation
Share to Disease Models, Animal
Share to Enzyme Replacement Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Hematopoietic Stem Cell Transplantation

Share to Phenotype

Source

Identifiers

PMID: 25345098

Genes

GUSB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mucopolysaccharidosis type VII: A powerful experimental system and therapeutic challenge.PMID 25345098Read ↗

Murine mucopolysaccharidosis VIL: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease.Semantic proximity Read ↗

Disease pathology signatures in a mouse model of Mucopolysaccharidosis type IIIBSemantic proximity Read ↗

Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseasesSemantic proximity Read ↗

Animal models for mucopolysaccharidosis disorders and their clinical relevanceSemantic proximity Read ↗

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?Semantic proximity Read ↗

Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatmentSemantic proximity Read ↗

Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.Semantic proximity Read ↗

Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.Semantic proximity Read ↗

Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrolSemantic proximity Read ↗

Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.Semantic proximity Read ↗

Phase I and II clinical trials for the mucopolysaccharidosesSemantic proximity Read ↗

Mucopolysaccharidosis III: Molecular basis and treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.